- Steve Bates OBE FMedSci – The UK Government’s Life Sciences Officer, who presented his vision for the future of the sector.
- Chris Baker – Discussed the investment landscape, emphasising that genuine patient impact is the ultimate differentiator.
- Hoyin Lam, PhD – Participated in a panel discussion on partnerships and licensing with pharmaceutical companies.
- Pragmatic optimism – Despite ongoing challenges, there was a shared sense of optimism for the future of the UK and European oncology ecosystem.
- Focus on patient outcomes – A core message throughout the day was that true innovation must translate into tangible improvements for patients, rather than technological “bells and whistles”.
- Importance of unique data – The significance of capturing distinctive patient data to create a “flywheel for innovation” was strongly emphasised.